Marfan syndrome

International Harrington Prize Awarded to Dr. Arlene Sharpe

Retrieved on: 
星期二, 三月 19, 2024
LDL, Human papillomavirus infection, Patient, DSM-IV codes, Lecture, National Cancer Institute, Harvard University, Creativity, AAP, PD-1, Massachusetts General Hospital, Science, Diabetes, Marfan syndrome, All India Mahila Congress, Immunology, AUC, NIH, Cancer, Nivolumab, Immune system, Biochemistry, Harvard Medical School, Cervical cancer, Research, University, Antibody, ASCI, FDA, Mount Sinai Hospital, Sickle cell disease, University of Pennsylvania, PCSK9, COVID-19, Doctor of Philosophy, Biology, Kidney, Thalassemia, Johns Hopkins University, Society, Division, Leptin, Pharmaceutical industry

CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School. The award recognizes her breakthrough discoveries in immune regulation, which have established foundational principles in immunology and led to new cancer therapies that act by boosting the immune response to cancer.

Key Points: 
  • CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School.
  • Her work helped identify key pathways that restrain the activity of T lymphocytes (immune cells) to fight cancer.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers globally before selecting the 2024 Harrington Prize recipient.
  • 2023: Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their groundbreaking translational research to restore sight in inherited genetic diseases.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
星期二, 一月 30, 2024
SAN, Breast, University, International, MD Anderson Cancer Center, FACMG, FDA, VAF, Bone marrow, SVS, Cytogenetics, Genome, LRS, OGM, University of Toronto, TNBC, Pressure, Biomarker, PARP, Quality control, Karyotype, HRD, Saint John Regional Hospital, T-ALL, CRISPR, Curie Institute, Triple-negative breast cancer, In situ hybridization, FISH, Frog, Genomics, Hospital, HRP, Patient, Marfan syndrome, Fluorescence, NIST, DSM-IV codes, Doctor of Philosophy, Cancer, Multiple myeloma, Workflow, Gene editing, Research, KT, Cell, Down syndrome, NGS, Vaccine

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

With One-in-Fifty People in the US at Risk, the Brain Aneurysm Foundation Launches New Campaign to Increase Disease Awareness and Accelerate Research

Retrieved on: 
星期三, 九月 6, 2023
Survivor, Fibromuscular dysplasia, Marfan syndrome, Beth Israel Deaconess Medical Center, Education, Prevalence, Blood, Stroke, Policy, Aortic rupture, Skull, Research, Brain, Risk, Pop, Pain, Subarachnoid hemorrhage, Polycystic kidney disease, BAF, Rupture, Patient, Physician, Need, Seizure, Nerve, Nausea, Biology, Diagnosis, City, Headache, Woman, Smoking, Death, Family, Memory, Social media, Autosome, Disease, Ehlers–Danlos syndromes, Pharmaceutical industry, Nursing, Aneurysm

HANOVER, Mass., Sept. 6, 2023 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced the launch of "Stop the Pop," a new campaign to increase awareness of the prevalence and impact of the disease and the need for ongoing investment to fund new innovations, screening, and treatment. 

Key Points: 
  • The campaign aims to build awareness of symptoms, genetic and environmental risk factors, and to increase research funding to better understand the underlying causes of the condition and to advance new treatments.
  • "A feeling that something has 'popped' is what we hear most from patients who have experienced a rupture.
  • A brain aneurysm is a weak, bulging area in an artery in the brain that in some instances can rupture.
  • Women over the age of 55 have a higher risk of brain aneurysm rupture than men and are generally at greater risk.

MasterControl Celebrates EMEA Customers’ Achievements in 2023

Retrieved on: 
星期三, 六月 7, 2023
Marfan syndrome, ISO, Elekta, SALT, MDSAP, European Masters, Transplant, Organization, Klosterfrau Melissengeist, Patient, Digital transformation, International Design Excellence Awards, Conference, Nursing, Pharmaceutical industry

These awards recognise MasterControl customers who have excelled in quality and manufacturing innovation and are leaders in their respected professions.

Key Points: 
  • These awards recognise MasterControl customers who have excelled in quality and manufacturing innovation and are leaders in their respected professions.
  • De Koning has been an influential leader in quality management working closely with IT to make certain they are using MasterControl and other technology to its full potential.
  • By using MasterControl Insights, Klosterfrau is able to easily generate reports across different sites, saving time and increasing visibility across operations.
  • “Each one of these organizations are positively impacting patient lives and MasterControl is honored to be a partner to these amazing companies and individuals.”

Statement on Aortic Aneurysm Reflecting on the Death of Grant Wahl

Retrieved on: 
星期三, 十二月 14, 2022
Ehlers–Danlos syndromes, Heart, CT, Degenerative disease, MD, Cardiology, Marfan syndrome, American Heart Association, American College, Life, Diagnosis, Skin, The Marfan Foundation, Washington University School of Medicine, MRI, Blood, Thoracic aortic aneurysm, Science, 2009 Davis Cup, Friends, Dissection, American College of Cardiology, Death, Wahl, Aortic aneurysm, Barnes-Jewish Hospital, Family, Nonsyndromic deafness, Intelligence, Child, Aneurysm, Woman, Multimedia, TAA, Microdeletion syndrome, Education, Pain scale, RENT, Connective tissue, Genetic testing, Joint, Blood vessel, Nervous system, Risk, Medical device, Pharmaceutical industry, Hospital

NEW YORK, Dec. 14, 2022 /PRNewswire/ -- The Marfan Foundation is saddened to learn that journalist Grant Wahl has died due to complications of an ascending thoracic aortic aneurysm.  Diagnosed, this condition can be treated if people and their health professionals know the risk and manageable complications.

Key Points: 
  • NEW YORK, Dec. 14, 2022 /PRNewswire/ -- The Marfan Foundation is saddened to learn that journalist Grant Wahl has died due to complications of an ascending thoracic aortic aneurysm.
  • We commit to continued investment in science, patient support, and collaborative efforts that will make these tragic moments fewer and fewer.
  • Recently, the American Heart Association and American College of Cardiology published new guidelines for identifying and treating aortic disease.
  • The Foundation, established more than 40 years ago, has been the leading advocate for aortic disease awareness and education since the death of Jonathan Larson, composer and playwright of RENT, who died of an undiagnosed aortic aneurysm and aortic dissection in 1995.

Nominations Open for 10th Annual International Harrington Prize for Innovation in Medicine

Retrieved on: 
星期一, 七月 25, 2022
Lecture, University Hospitals Cleveland Medical Center, NHLBI, Association, Antibody, Diabetes, Rockefeller University, NIH, Society, University, NIAMS, Disorder, Sickle cell disease, Doctor of Philosophy, American Physician Scientists Association, CAR, Human papillomavirus infection, Massachusetts General Hospital, Leptin, Lists of diseases, Vanderbilt University, Marfan syndrome, Mount Sinai Hospital, National Cancer Institute, LDL, COVID-19, Cervical cancer, All India Mahila Congress, Thalassemia, Organization, Journal, University of Texas Southwestern Medical Center, Creativity, Science, List, Patient, University of Copenhagen, University of Pennsylvania, Biology, American Society for Clinical Investigation, PCSK9, ASCI, APSA, Johns Hopkins University, AAP, Harvard University, Pharmaceutical industry, Vaccine, Medicine, MD

CLEVELAND, July 25, 2022 /PRNewswire/ -- National and international nominations are being sought for the 2023 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application. 

Key Points: 
  • CLEVELAND, July 25, 2022 /PRNewswire/ --National and international nominations are being sought for the 2023 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application.
  • The Harrington Prize, which carries a $20,000 honorarium, is a collaboration between Harrington Discovery Institute at University Hospitals in Cleveland, Ohio and the American Society for Clinical Investigation (ASCI), one of the nation's oldest and most respected medical honor societies.
  • Harrington Discovery Institute is a nonprofit institute dedicated to helping physician-scientists accelerate promising discoveries into medicines for unmet needs.
  • A committee composed of members of the Harrington Discovery Institute Scientific Advisory Board and the ASCI Council will review the nominations and select the awardee.

Insights on the Preimplantation Genetic Testing Global Market to 2027 - North America Dominates the Industry - ResearchAndMarkets.com

Retrieved on: 
星期四, 五月 12, 2022
Health, General Health, Chromosome, Death, IVF, Genetic testing, Asthma, World, HSCT, Degenerative disease, Patient, Cystic fibrosis, Parent, Government, Bone marrow, Aneuploidy, Pneumonia, COVID-19, HLA, Lists of diseases, Awareness, Down syndrome, Immune system, CAGR, Marfan syndrome, Prevalence, Diagnosis, UNICEF, Vaccine, Pharmaceutical industry, Medical device, Growth

The "Preimplantation Genetic Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Preimplantation Genetic Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The preimplantation genetic testing market studied was anticipated to grow with a CAGR of 10.5% during the forecast period.
  • The HLA typing by application segment is expected to account for the largest held the largest of the pre-implantation genetic testing market.
  • North America is expected to dominate the pre-implantation genetic testing market.

International Harrington Prize Jointly Awarded to Drs. James Crowe and Michel Nussenzweig

Retrieved on: 
星期四, 三月 24, 2022
University of Texas Southwestern Medical Center, AAP, National Cancer Institute, Mount Sinai Hospital, Cardiology, Rockefeller University, University, Johns Hopkins University, Biochemistry, LDL, Massachusetts General Hospital, Pediatrics, PCSK9, All India Mahila Congress, Harvard University, University Hospitals Cleveland Medical Center, Disorder, Biology, NIH, ASCI, Science, Degenerative disease, Thalassemia, Doctor of Philosophy, Disease, Severe acute respiratory syndrome coronavirus 2, Marfan syndrome, Diabetes, Society, COVID, Patient, Creativity, Antibody, Human, Academic health science centre, Microbiology, University of Pennsylvania, Pathology, CAR, Immunology, Human papillomavirus infection, COVID-19, Sickle cell disease, Northwestern Medicine, HHMI, Division, Pharmaceutical industry, Vaccine, MD, Medicine

CLEVELAND, March 24, 2022 /PRNewswire/ -- The ninth annual Harrington Prize for Innovation in Medicine has been jointly awarded to James E. Crowe, Jr., MD, Director, Vanderbilt Vaccine Center and Professor, Departments of Pediatrics and Pathology, Microbiology and Immunology, Vanderbilt School of Medicine, and Michel C. Nussenzweig, MD, PhD, Investigator, HHMI, and Zanvil A. Cohn and Ralph M. Steinman Professor, The Rockefeller University. The award recognizes their groundbreaking work, which has elucidated fundamental principles of the human immune response and enabled the use of human antibodies to treat COVID-19.

Key Points: 
  • Dr. Crowe has advanced the discovery of human monoclonal antibodies for many of the most pathogenic viruses that cause human disease.
  • Dr. Nussenzweig showed that antibodies cloned directly from humans can be a safe and effective treatment against viral infections when passively transferred to other humans.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers from eight countries before selecting the 2022 Harrington Prize recipients.
  • Crowe and Nussenzweig are extraordinary physician-scientists who took distinct and separate paths but arrived at the same endpoint.

Dr. Luciana Young Named Vice Chair of Inteleos Board of Directors

Retrieved on: 
星期四, 一月 13, 2022
POCUS, Board, Patient, American Registry for Diagnostic Medical Sonography, University, Alliance, Seattle Children's, Echocardiography, Cardiology, Board of directors, ARDMS, Aorta, Intelligence, Heart, University of Washington Department of Global Health, Hospital, Diagnostic medical sonography, APCA, FACC, Partnership, FAHA, Marfan syndrome, Management, Medical device, MD

ROCKVILLE, Md., Jan. 13, 2022 /PRNewswire/ -- Inteleos™, a non-profit global healthcare certification organization, today named pediatric cardiologist Dr. Luciana Young, MD, FASE, FAHA, FACC, as vice chair of its Board of Directors through 2023. An Inteleos volunteer since 2006 and board member since 2012, Dr. Young will work closely with incoming Board Chair Dr. Michael Lilly and CEO/Executive Director Dale R. Cyr to advance Inteleos' mission of upholding the highest standards in healthcare and patient safety.

Key Points: 
  • ROCKVILLE, Md., Jan. 13, 2022 /PRNewswire/ -- Inteleos , a non-profit global healthcare certification organization, today named pediatric cardiologist Dr. Luciana Young, MD, FASE, FAHA, FACC, as vice chair of its Board of Directors through 2023.
  • An Inteleos volunteer since 2006 and board member since 2012, Dr. Young will work closely with incoming Board Chair Dr. Michael Lilly and CEO/Executive Director Dale R. Cyr to advance Inteleos' mission of upholdingthe highest standards in healthcare and patient safety.
  • "Luciana has contributed to our mission for years with a rare combination of passion, intelligence, and experience," said Dr. Lilly.
  • As vice chair, Dr. Young will chair the Inteleos board's nominating committee and serve on the executive and compensation committees.

Dr. Luciana Young Named Vice Chair of Inteleos Board of Directors

Retrieved on: 
星期四, 一月 13, 2022
POCUS, Board, Patient, American Registry for Diagnostic Medical Sonography, University, Alliance, Seattle Children's, Echocardiography, Cardiology, Board of directors, ARDMS, Aorta, Intelligence, Heart, University of Washington Department of Global Health, Hospital, Diagnostic medical sonography, APCA, FACC, Partnership, FAHA, Marfan syndrome, Management, Medical device, MD

ROCKVILLE, Md., Jan. 13, 2022 /PRNewswire/ -- Inteleos™, a non-profit global healthcare certification organization, today named pediatric cardiologist Dr. Luciana Young, MD, FASE, FAHA, FACC, as vice chair of its Board of Directors through 2023. An Inteleos volunteer since 2006 and board member since 2012, Dr. Young will work closely with incoming Board Chair Dr. Michael Lilly and CEO/Executive Director Dale R. Cyr to advance Inteleos' mission of upholding the highest standards in healthcare and patient safety.

Key Points: 
  • ROCKVILLE, Md., Jan. 13, 2022 /PRNewswire/ -- Inteleos , a non-profit global healthcare certification organization, today named pediatric cardiologist Dr. Luciana Young, MD, FASE, FAHA, FACC, as vice chair of its Board of Directors through 2023.
  • An Inteleos volunteer since 2006 and board member since 2012, Dr. Young will work closely with incoming Board Chair Dr. Michael Lilly and CEO/Executive Director Dale R. Cyr to advance Inteleos' mission of upholdingthe highest standards in healthcare and patient safety.
  • "Luciana has contributed to our mission for years with a rare combination of passion, intelligence, and experience," said Dr. Lilly.
  • As vice chair, Dr. Young will chair the Inteleos board's nominating committee and serve on the executive and compensation committees.